Abstract 110P
Background
Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma with high metastatic propensity and is often diagnosed at advanced stages, raising public health concerns in its endemic regions such as South China and Southeast Asia. The study of NPC metastasis is hindered by the lack of appropriate models capable to recapitulate the heterogeneous tumour microenvironment in vitro. The current study aims to generate an in vitro model to represent the in vivo biology for NPC and characterize the spheroid invasion in real time.
Methods
To mimic the microenvironment encountered by NPC cells in vivo, heterotypic multicellular tumour spheroids (MCTSs) consisting of triple co-culture of NPC cells (HK-1), fibroblasts (MRC-5), and endothelial cells (HUVEC) was generated using a scaffold-based method. Through histological and immunofluorescence analyses, the morphological characteristic and the organization of the MCTSs were characterized. Tumour spheroid migration assays were conducted on the extracellular matrix (ECM). Quantitative real-time measurements of migration and invasion through an ECM barrier of the MCTSs were conducted by using a real-time cell analyser.
Results
Heterotypic MCTSs constituted from HK-1, MRC-5, and HUVEC formed irregular mass and stellate morphology structure, with loosely arranged cells observed as revealed by H&E staining. The cells demonstrated tumour features including high chromatic and pleomorphism, high nuclear-to-cytoplasmic ratio, mitosis, and necrosis. Immunofluorescence staining showed the presence of NPC cells, fibroblasts, and endothelial cells in the heterotypic MCTSs. Through real-time cell monitoring, this heterotypic MCTSs showed migration and invasion at 1:10 Matrigel with 0.5 μg/μl fibronectin.
Conclusions
The three-dimensional model generated in this study successfully reconstructed the in vivo biology of NPC. To our knowledge, this is the first report on NPC spheroid model that incoporate both tumour and stromal cells. 3D co-culture spheroid is holding a great promise as next generation standard of in vitro pre-clinical model for biomarkers discovery, accelerating drug screening process, and achieving a more precise personalized treatment for cancer patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fundamental Research Grant Scheme FRGS (FGRS/1/2020/SKK0/UCSI/02/2) by Ministry of Higher Education (MOHE) Malaysia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract